Our products are designed to make that happen.
Developed for People. Reformulated for Pets.
We know what the future of pet health looks like because it’s already here for humans.
We tailor medicines that have transformed the lives of tens of thousands of human patients to improve the lives of pets most in need.
We address some of the most common pet issues where current solutions don’t exist or fall short.
Human Blockbuster Pet Specific |
Market Segment | Repurpose for Pets | Proof-of-Concept | Pilot Study | FDA Critical Path | Commercial Ready 1 | |
|---|---|---|---|---|---|---|---|
| Ozempic | OKV-119 |  Obesity |
2028 |
||||
 Obesity |
2028 |
||||||
| Diabetes |
2029 |
||||||
| CKD |
2029 |
||||||
| Longevity 2 |
2029 |
||||||
| Longevity 2 |
2029 |
||||||
| CellCept / Myfortic | OKV-1001 | Atopic Dermatitis |
2028 |
||||
| Arthritis |
2028 |
||||||
| Autoimmune Inflammation 2 |
2028 |
||||||
1 FDA/EMA regulatory filings
2 Conditional approval
Ozempic is a registered trademark of Novo Nordisk, CellCept is a registered trademark of Roche; Myfortic is a registered trademark of Novartis
Human medicine is our crystal ball.
Leveraging decades and billions of human R&D investments allows us to:
